PDCD1 and colorectal carcinoma: Currently, immunotherapy has shown impressive efficacy in the treatment of multiple malignancies, including advanced CRC, through immune checkpoint blockade with antibodies targeting the PD‐1/PD‐L1 pathway.9, 10